Investor Presentation September 2021
Quarter Ended Jun 30, 2021
Total revenue of $351.7 million, up 6% from $330.3 million for the prior-year period.
Net income of $74.0 million, compared to $84.0 million for the prior-year period.
Net income attributable to ApolloMed increased to $25.8 million, from $11.1 million for the prior-year period.
For complete information regarding our financials, see our periodic filings
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner.